Japan Neurodegenerative Disease Market

ID: MRFR/LS/50853-HCR

200 Pages

Rahul Gotadki

September 2025

Japan Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal)-Forecast to 2035

Japan Neurodegenerative Disease Market Research Report-Forecast to 2035 Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Japan Neurodegenerative Disease Market Summary

The Japan Neurodegenerative Disease market is projected to grow from 1.46 USD Billion in 2024 to 2.66 USD Billion by 2035.

Key Market Trends & Highlights

Japan Neurodegenerative Disease Key Trends and Highlights

The market is expected to achieve a compound annual growth rate of 5.6 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 2.66 USD Billion, indicating robust growth potential.
In 2024, the market is valued at 1.46 USD Billion, reflecting the current demand for neurodegenerative disease treatments.
Growing adoption of advanced therapeutic technologies due to increasing prevalence of neurodegenerative diseases is a major market driver.

Japan Neurodegenerative Disease Market

CAGR

5.6%

Market Size & Forecast

2024 Market Size	1.46 (USD Billion)
2035 Market Size	2.66 (USD Billion)
CAGR (2025-2035)	5.6%

Major Players

Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Eisai Co, Pfizer, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis, Astellas Pharma, Sumitomo Dainippon Pharma, Biogen, Roche, Amgen, Ono Pharmaceutical

Japan Neurodegenerative Disease Market Trends

The Japan Neurodegenerative Disease Market is experiencing significant trends driven by demographic shifts and advancements in medical research. One of the key market drivers in Japan is the increasing aging population, with a higher prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's among older adults. The government has recognized these health concerns and is enhancing healthcare policies to support research initiatives and improve care facilities for affected individuals. Moreover, advancements in biotechnology and digital health are creating new avenues for diagnosis and therapy, leading to innovative treatments that can improve patient outcomes.

Opportunities to be explored include collaboration between healthcare providers and technology firms to integrate artificial intelligence and telemedicine solutions into care strategies. There is a growing interest in personalized medicine, which tailors treatments based on genetic and lifestyle factors, presenting a chance for pharmaceutical companies to develop niche products that cater specifically to Japanese patients. Furthermore, increasing public awareness about neurodegenerative disorders is prompting more individuals to seek medical advice earlier, thus spurring demand for effective therapies.

In recent times, there has been a noticeable trend towards preventive care and early intervention.With the government promoting awareness campaigns, there is a push for routine screenings and early diagnostics to identify neurodegenerative diseases at stages when treatments can be more effective. Additionally, greater emphasis on mental health support is reshaping the landscape of care, fostering an environment where mental well-being is pivotal to the management of neurodegenerative diseases. Overall, the interactions between technological advancements and demographic realities are setting the stage for transformation in Japan's neurodegenerative disease market.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Market Segment Insights

Japan Neurodegenerative Disease Market Segment Insights

Neurodegenerative Disease Market Disease Type Insights

The Japan Neurodegenerative Disease Market experiences notable growth driven by various disease types, including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease. Alzheimer's Disease remains a critical concern, as it affects millions of elderly individuals in Japan, leading to a significant demand for effective therapies and supportive care. Its progressive nature necessitates ongoing Research and Development efforts and innovative treatment solutions to improve the quality of life for both patients and caregivers.

Parkinson's Disease also holds substantial importance with its rising prevalence, creating a population in need of specialized management options and therapeutics aimed at alleviating symptoms and maintaining mobility. Multiple Sclerosis represents another significant facet of the market, largely impacting younger populations with often debilitating symptoms that require long-term treatment and support. The focus is on developing therapies that not only address flare-ups but also enhance overall living conditions for those afflicted.

Amyotrophic Lateral Sclerosis is a less common yet severe neurodegenerative disorder, necessitating comprehensive care approaches and highlighting the urgency for governmental and private sector involvement in funding Research and Development initiatives. Finally, Huntington’s Diseasethough rarercarries significant implications for families, heightening the importance of genetic counseling, community support networks, and innovative treatment paradigms. Despite the challenges posed by these neurodegenerative disorders, the evolving landscape of the Japan Neurodegenerative Disease Market presents numerous opportunities.

The increasing awareness and focus on neurodegenerative conditions signal shifts in societal attitudes toward these disorders, driving the demand for effective management solutions and supportive services, which can substantially enhance patients lives and experiences throughout this challenging journey.

Neurodegenerative Disease Market Diagnosis Method Insights

The Diagnosis Method segment of the Japan Neurodegenerative Disease Market is pivotal in identifying and managing various neurodegenerative disorders effectively. Within this segment, Neurological Examinations are fundamental as they assess the physical and mental functions of patients, highlighting symptoms indicative of diseases like Alzheimer's and Parkinson's. Imaging Techniques, such as MRI and CT scans, provide critical visual insights into brain structure and functioning, aiding in the early detection of these conditions.

Cerebrospinal Fluid Analysis offers a deeper understanding of neurological conditions by analyzing the fluid surrounding the brain and spinal cord, contributing to the diagnosis of specific disorders.Electrophysiological Tests, which measure the electrical activity of the brain and nerves, play an essential role in diagnosing conditions by revealing abnormalities in nerve and muscle function. The combination of these methods provides a comprehensive toolkit for clinicians, enabling timely and accurate diagnoses, which is crucial given the growing prevalence of neurodegenerative diseases in Japan.

As the population ages, the significance of these diagnosis methods is expected to increase, driving advancements in technologies that enhance diagnosis accuracy and speed, thus playing an important role in improving patient outcomes in the Japan Neurodegenerative Disease Market.

Neurodegenerative Disease Market Treatment Type Insights

The Treatment Type segment of the Japan Neurodegenerative Disease Market showcases a comprehensive array of options catering to the specific needs of patients suffering from various neurodegenerative conditions. Medication remains a cornerstone in managing symptoms and improving patients' quality of life, with ongoing advancements in drug formulation and therapeutic approaches highlighting its essential role in treatment programs.

Therapy, including both physical and cognitive strategies, is highly emphasized for improving functionality and emotional support, underlining its significance in holistic patient care.Rehabilitation forms an integral aspect of recovery, focusing on regaining lost skills and enhancing daily living activities, thereby easing the burden on caregivers and the healthcare system. Meanwhile, Surgical Interventions are critical for cases requiring more aggressive treatments, particularly in conditions like Parkinson’s disease, where procedures can significantly reduce symptoms.

As Japan faces an aging population, reflecting increasing rates of neurodegenerative diseases, the focus on these treatment approaches is vital in addressing the growing healthcare challenges and ensuring that patients receive comprehensive and effective care tailored to their needs.The anticipation of a growing prevalence of these disorders emphasizes the importance of continual innovation and investment in research within these treatment types.

Neurodegenerative Disease Market Route of Administration Insights

The Route of Administration segment within the Japan Neurodegenerative Disease Market plays a pivotal role in delivering therapies effectively to patients suffering from conditions such as Alzheimer’s and Parkinson's disease. Each routefrom Oral to Injectable, Intravenous, and Transdermaloffers unique advantages that cater to diverse patient needs. Oral administration remains a popular choice due to its ease of use and patient compliance; it provides a convenient option for long-term management of chronic neurodegenerative disorders.

Injectable methods, particularly for biologics, are significant for achieving rapid therapeutic effects and controlling dosing more tightly.Intravenous administration ensures immediate drug action, making it essential in acute care settings or during hospitalization. Transdermal delivery is emerging as a valuable alternative, allowing for steady release of medication and reducing gastrointestinal side effects. As the aging population in Japan continues to grow, the demand for innovative and efficient Routes of Administration is expected to surge, correspondingly increasing its significance within the Japan Neurodegenerative Disease Market.

The Japanese government's focus on innovative healthcare solutions further underscores the importance of optimizing drug delivery methods in enhancing patient outcomes.

Get more detailed insights about Japan Neurodegenerative Disease Market Research Report-Forecast to 2035

Request Free Sample

Key Players and Competitive Insights

The Japan Neurodegenerative Disease Market is characterized by intense competition, driven by an increasing prevalence of various neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. This landscape involves numerous established pharmaceutical companies seeking to leverage innovative therapies and cutting-edge research in order to address the unmet medical needs of patients suffering from these debilitating diseases. The market dynamics are influenced by several factors, including the aging population, healthcare policies, advancements in drug development technologies, and a keen focus on improving patient outcomes.

Understanding the competitive insights of this market is crucial for companies as they navigate regulatory frameworks, market entry strategies, and product development pathways to establish a strong foothold in this vital sector. Chugai Pharmaceutical is a notable player in the Japan Neurodegenerative Disease Market, fortified by its strong commitment to research and development as well as its robust portfolio of innovative therapeutics. The company has developed specialized knowledge in the field of biologics and customized medicines, which enhances its position within the Japan market.

Additionally, Chugai Pharmaceutical benefits from strong partnerships with global pharmaceutical firms that bolster its capacity for clinical trials and enhance its distribution networks. This reliance on collaborations not only fortifies its product offerings but also streamlines its operational efficiencies. The company's focus on neurodegenerative diseases allows it to bring forward potential breakthroughs that have the capability of significantly improving patient quality of life while maintaining a deep understanding of the local market dynamics and regulatory environment.Daiichi Sankyo is another significant entity within the Japan Neurodegenerative Disease Market, recognized for its comprehensive approach to developing and providing solutions for neurodegenerative conditions.

The company boasts a diverse range of key products and services that cater specifically to the symptoms and treatment protocols associated with neurodegenerative diseases. Daiichi Sankyo's strong market presence is further augmented by strategic mergers and acquisitions which have expanded its research capabilities and therapeutic focus. These initiatives not only consolidate its position within the industry but also enhance its portfolio with groundbreaking therapies aimed at treating Alzheimer's and similar neurodegenerative disorders.

The company’s strengths lie in its innovative pipeline and established reputation, facilitating effective engagement with healthcare providers and ensuring that its offerings align with patient needs and evolving market demands in Japan.

Key Companies in the Japan Neurodegenerative Disease Market market include

Industry Developments

The Japan Neurodegenerative Disease Market is witnessing significant developments, particularly from key players like Eisai Co. and Takeda Pharmaceutical. In recent months, Eisai announced promising interim results for its Alzheimer's treatment, lecanemab, indicating a potential boost in market share and influence in the treatment landscape. The Japanese government continues to support healthcare innovation through its "Healthcare Policy 2020", prioritizing dementia care and funding research initiatives to enhance patient outcomes. In the context of mergers and acquisitions, Takeda Pharmaceutical recently acquired an innovative neurodegenerative disease treatment technology from a smaller firm in November 2022, strengthening its pipeline in this sector.

Chugai Pharmaceutical has also been focusing on its R&D endeavors, particularly in developing therapies for amyotrophic lateral sclerosis. The Japanese market is projected to grow significantly due to a rising aging population, with estimates suggesting that the number of dementia patients will reach approximately 7 million by 2025. Astellas Pharma's investments in gene therapy are indicative of the proactive strategies employed by companies to address the surging prevalence of neurodegenerative disorders in Japan.

Market Segmentation

Outlook

Oral
Injectable
Intravenous
Transdermal

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	1.38(USD Billion)
MARKET SIZE 2024	1.46(USD Billion)
MARKET SIZE 2035	2.66(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.611% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Eisai Co, Eisai, Pfizer, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis, Astellas Pharma, Sumitomo Dainippon Pharma, Biogen, Roche, Amgen, Ono Pharmaceutical
SEGMENTS COVERED	Disease Type, Diagnosis Method, Treatment Type, Route of Administration
KEY MARKET OPPORTUNITIES	Aging population increasing treatment demand, Innovative therapeutics and drug development, Biomarker discovery for early diagnosis, Growing telemedicine adoption, Partnerships for research funding
KEY MARKET DYNAMICS	Aging population, Increasing healthcare expenditure, Rising awareness and diagnosis, Advancements in treatment options, Strong research and development initiatives
COUNTRIES COVERED	Japan

FAQs

What is the estimated market size of the Japan Neurodegenerative Disease Market in 2024?

The Japan Neurodegenerative Disease Market is expected to be valued at 1.46 USD Billion in 2024.

What will be the market size for the Japan Neurodegenerative Disease Market by 2035?

By 2035, the market is projected to reach a value of 2.66 USD Billion.

What is the expected compound annual growth rate (CAGR) for the Japan Neurodegenerative Disease Market from 2025 to 2035?

The expected CAGR for the market is 5.611% during the period from 2025 to 2035.

Which disease type holds the largest market value in 2024 within the Japan Neurodegenerative Disease Market?

Alzheimer's Disease holds the largest market value at 0.58 USD Billion in 2024.

What is the projected value of Parkinson's Disease in the Japan Neurodegenerative Disease Market by 2035?

The projected value of Parkinson's Disease in the market is expected to reach 0.67 USD Billion by 2035.

Who are the key players in the Japan Neurodegenerative Disease Market?

Major players include Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, and Eisai Co among others.

What is the market value for Multiple Sclerosis in 2024 within Japan's Neurodegenerative Disease Market?

The market value for Multiple Sclerosis is anticipated to be 0.22 USD Billion in 2024.

What are the growth challenges faced by the Japan Neurodegenerative Disease Market?

The market faces challenges such as high drug development costs and regulatory hurdles.

What is the expected market value for Amyotrophic Lateral Sclerosis in 2035?

The expected market value for Amyotrophic Lateral Sclerosis is forecasted to be 0.25 USD Billion by 2035.

How does the market for Huntington's Disease look from 2024 to 2035?

The market for Huntington's Disease is expected to grow from 0.14 USD Billion in 2024 to 0.25 USD Billion by 2035.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027